The Danish observational cohort study published in the Journal of Internal Medicine (Hansen et al., 2026) tracked 50,771 new aspirin initiators and 156,191 NSAID starters against population controls, revealing elevated cystoscopy rates among aspirin users alongside a shift toward earlier-stage bladder cancer diagnoses. This large-scale, non-randomized design (sample >200,000) carries inherent confounding risks from indication bias and lacks the causal rigor of an RCT, yet its population registry linkage minimizes loss to follow-up. Aspirin’s irreversible COX-1 inhibition impairs platelet aggregation more potently than most NSAIDs, converting microscopic hematuria into visible bleeding that prompts diagnostic workup—potentially explaining the lower invasive-stage prevalence at detection. Prior research in JAMA Oncology (2022) on 1.2 million Nordic adults linked low-dose aspirin to modestly reduced bladder cancer mortality, while a 2023 meta-analysis in European Urology (n=18 cohorts) noted inconsistent chemopreventive signals confounded by detection bias. The MedicalXpress coverage underplays how this mechanism reframes aspirin not merely as a bleeding risk but as an inadvertent screening adjunct; clinicians should therefore treat new gross hematuria in aspirin users as an urgent red flag rather than a side-effect nuisance. No industry conflicts were declared, strengthening credibility, though generalizability beyond Denmark’s uniform healthcare access remains uncertain.